PQ 441
441. Deputy Denis Naughten asked the Minister for Health the reason Pioglitazone remains an approved drug under the GMS for the treatment of diabetes in view of the fact that the US Food and Drug Administration has found it to be associated with bladder tumours; and if he will make a statement on the matter. [4367/19]
Introduced
29 January 2019
Last action
—
Status
written
Sponsors
—
Subjects
Discovery layer
Source updated
29 January 2019
Summary
441. Deputy Denis Naughten asked the Minister for Health the reason Pioglitazone remains an approved drug under the GMS for the treatment of diabetes in view of the fact that the US Food and Drug Administration has found it to be associated with bladder tumours; and if he will make a statement on the matter. [4367/19]
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
1 official file
Medicinal Products Reimbursement
Medicinal Products Reimbursement
xml · EN · 29 January 2019
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.oireachtas.ie/en/debates/question/2019-01-29/441/
- Open data entity: https://data.oireachtas.ie/ie/oireachtas/question/2019-01-29/pq_441